Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity.

Saved in:
Bibliographic Details
Main Authors: van der Lubbe, Joan E.M., Rosendahl Huber, Sietske K., Vijayan, Aneesh, Dekking, Liesbeth, van Huizen, Ella, Vreugdenhil, Jessica, Choi, Ying, Baert, Miranda R.M., Feddes-de Boer, Karin, Izquierdo Gil, Ana, van Heerden, Marjolein, Dalebout, Tim J., Myeni, Sebenzile K., Kikkert, Marjolein, Snijder, Eric J., de Waal, Leon, Stittelaar, Koert J., Tolboom, Jeroen T.B.M., Serroyen, Jan, Muchene, Leacky, van der Fits, Leslie, Rutten, Lucy, Langedijk, Johannes P.M., Barouch, Dan H., Schuitemaker, Hanneke, Zahn, Roland C., Wegmann, Frank
Format: Article/Letter to editor biblioteca
Language:English
Subjects:Life Science,
Online Access:https://research.wur.nl/en/publications/ad26cov2s-protects-syrian-hamsters-against-g614-spike-variant-sar
Tags: Add Tag
No Tags, Be the first to tag this record!
id dig-wur-nl-wurpubs-581138
record_format koha
spelling dig-wur-nl-wurpubs-5811382025-01-14 van der Lubbe, Joan E.M. Rosendahl Huber, Sietske K. Vijayan, Aneesh Dekking, Liesbeth van Huizen, Ella Vreugdenhil, Jessica Choi, Ying Baert, Miranda R.M. Feddes-de Boer, Karin Izquierdo Gil, Ana van Heerden, Marjolein Dalebout, Tim J. Myeni, Sebenzile K. Kikkert, Marjolein Snijder, Eric J. de Waal, Leon Stittelaar, Koert J. Tolboom, Jeroen T.B.M. Serroyen, Jan Muchene, Leacky van der Fits, Leslie Rutten, Lucy Langedijk, Johannes P.M. Barouch, Dan H. Schuitemaker, Hanneke Zahn, Roland C. Wegmann, Frank Article/Letter to editor npj Vaccines 6 (2021) 1 ISSN: 2059-0105 Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease 2021 Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity. en application/pdf https://research.wur.nl/en/publications/ad26cov2s-protects-syrian-hamsters-against-g614-spike-variant-sar 10.1038/s41541-021-00301-y https://edepot.wur.nl/544790 Life Science https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ Wageningen University & Research
institution WUR NL
collection DSpace
country Países bajos
countrycode NL
component Bibliográfico
access En linea
databasecode dig-wur-nl
tag biblioteca
region Europa del Oeste
libraryname WUR Library Netherlands
language English
topic Life Science
Life Science
spellingShingle Life Science
Life Science
van der Lubbe, Joan E.M.
Rosendahl Huber, Sietske K.
Vijayan, Aneesh
Dekking, Liesbeth
van Huizen, Ella
Vreugdenhil, Jessica
Choi, Ying
Baert, Miranda R.M.
Feddes-de Boer, Karin
Izquierdo Gil, Ana
van Heerden, Marjolein
Dalebout, Tim J.
Myeni, Sebenzile K.
Kikkert, Marjolein
Snijder, Eric J.
de Waal, Leon
Stittelaar, Koert J.
Tolboom, Jeroen T.B.M.
Serroyen, Jan
Muchene, Leacky
van der Fits, Leslie
Rutten, Lucy
Langedijk, Johannes P.M.
Barouch, Dan H.
Schuitemaker, Hanneke
Zahn, Roland C.
Wegmann, Frank
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
description Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate SARS-CoV-2 infection models. Here, we investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a moderate disease Syrian hamster challenge model, using the currently most prevalent G614 spike SARS-CoV-2 variant. Vaccine doses of 1 × 109 and 1 × 1010 VP elicited substantial neutralizing antibodies titers and completely protected over 80% of SARS-CoV-2 inoculated Syrian hamsters from lung infection and pneumonia but not upper respiratory tract infection. A second vaccine dose further increased neutralizing antibody titers that was associated with decreased infectious viral load in the upper respiratory tract after SARS-CoV-2 challenge. Suboptimal non-protective immune responses elicited by low-dose A26.COV2.S vaccination did not exacerbate respiratory disease in SARS-CoV-2-inoculated Syrian hamsters with breakthrough infection. In addition, dosing down the vaccine allowed to establish that binding and neutralizing antibody titers correlate with lower respiratory tract protection probability. Overall, these preclinical data confirm efficacy of a one-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity.
format Article/Letter to editor
topic_facet Life Science
author van der Lubbe, Joan E.M.
Rosendahl Huber, Sietske K.
Vijayan, Aneesh
Dekking, Liesbeth
van Huizen, Ella
Vreugdenhil, Jessica
Choi, Ying
Baert, Miranda R.M.
Feddes-de Boer, Karin
Izquierdo Gil, Ana
van Heerden, Marjolein
Dalebout, Tim J.
Myeni, Sebenzile K.
Kikkert, Marjolein
Snijder, Eric J.
de Waal, Leon
Stittelaar, Koert J.
Tolboom, Jeroen T.B.M.
Serroyen, Jan
Muchene, Leacky
van der Fits, Leslie
Rutten, Lucy
Langedijk, Johannes P.M.
Barouch, Dan H.
Schuitemaker, Hanneke
Zahn, Roland C.
Wegmann, Frank
author_facet van der Lubbe, Joan E.M.
Rosendahl Huber, Sietske K.
Vijayan, Aneesh
Dekking, Liesbeth
van Huizen, Ella
Vreugdenhil, Jessica
Choi, Ying
Baert, Miranda R.M.
Feddes-de Boer, Karin
Izquierdo Gil, Ana
van Heerden, Marjolein
Dalebout, Tim J.
Myeni, Sebenzile K.
Kikkert, Marjolein
Snijder, Eric J.
de Waal, Leon
Stittelaar, Koert J.
Tolboom, Jeroen T.B.M.
Serroyen, Jan
Muchene, Leacky
van der Fits, Leslie
Rutten, Lucy
Langedijk, Johannes P.M.
Barouch, Dan H.
Schuitemaker, Hanneke
Zahn, Roland C.
Wegmann, Frank
author_sort van der Lubbe, Joan E.M.
title Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
title_short Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
title_full Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
title_fullStr Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
title_full_unstemmed Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
title_sort ad26.cov2.s protects syrian hamsters against g614 spike variant sars-cov-2 and does not enhance respiratory disease
url https://research.wur.nl/en/publications/ad26cov2s-protects-syrian-hamsters-against-g614-spike-variant-sar
work_keys_str_mv AT vanderlubbejoanem ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT rosendahlhubersietskek ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT vijayananeesh ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT dekkingliesbeth ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT vanhuizenella ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT vreugdenhiljessica ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT choiying ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT baertmirandarm ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT feddesdeboerkarin ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT izquierdogilana ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT vanheerdenmarjolein ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT dalebouttimj ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT myenisebenzilek ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT kikkertmarjolein ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT snijderericj ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT dewaalleon ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT stittelaarkoertj ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT tolboomjeroentbm ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT serroyenjan ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT mucheneleacky ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT vanderfitsleslie ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT ruttenlucy ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT langedijkjohannespm ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT barouchdanh ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT schuitemakerhanneke ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT zahnrolandc ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
AT wegmannfrank ad26cov2sprotectssyrianhamstersagainstg614spikevariantsarscov2anddoesnotenhancerespiratorydisease
_version_ 1822266889295888384